- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07669155
Acute Normovolemic Hemodilution in Bone Cancer Surgery
The Effect of Acute Normovolemic Hemodilution on Requirement of Allogeneic Red Blood Cell in Patients Undergoing Bone Cancer Surgery
Malignant bone tumors often lead to skeletal complications, known as skeletal related events (SRE). These complications mainly include pathological fractures, severe pain, and spinal cord compression. Typically, SRE reduces overall survival rates and is associated with loss of mobility and social functioning, decreased quality of life, and significantly increased healthcare costs. Surgical resection is an important means of treating malignant bone tumors. The main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and/or nerve compression, or stabilizing pathological fractures. Surgery for malignant bone tumors often requires extensive exploration, osteotomy, and prosthetic reconstruction. The surgery involves significant trauma and excessive bleeding from the wound. Therefore, there is a significant risk of perioperative blood loss and transfusion during surgery for malignant bone tumors. However, blood transfusion also brings transfusion related risks to patients, increases the incidence of postoperative complications, and increases the healthcare burden on patients and society. Acute normovolemic hemodilution (ANH) may help reduce allogeneic red blood cell transfusion. However, There is a lack of high-quality evidence to support the use of ANH in bone cancer surgery.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Malignant bone tumors often lead to skeletal complications, known as skeletal related events (SRE). These complications mainly include pathological fractures, severe pain, and spinal cord compression. Typically, SRE reduces overall survival rates and is associated with loss of mobility and social functioning, decreased quality of life, and significantly increased healthcare costs. Surgical resection is an important means of treating malignant bone tumors. The main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and/or nerve compression, or stabilizing pathological fractures. Surgery for bone cancer often requires extensive exploration, osteotomy, and prosthetic reconstruction. The surgery involves significant trauma and excessive bleeding from the wound. Therefore, there is a significant risk of perioperative blood loss and transfusion during surgery for malignant bone tumors. However, blood transfusion also brings transfusion related risks to patients, increases the incidence of postoperative complications, and increases the healthcare burden on patients and society. Therefore, it is particularly important to develop a perioperative blood management (PBM) plan for these patients. Acute normovolemic hemodilution (ANH) may help reduce allogeneic red blood cell transfusion. However, There is a lack of high-quality evidence to support the use of ANH in bone cancer surgery.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Beijing, China, 100034
- Peking University First Hospital
-
Beijing, China, 100035
- Beijing Jishuitan Hospital
-
Shanghai, China, 200032
- Fudan University Shanghai Cancer Center
-
Shanghai, China, 200080
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
-
Shanghai, China, 200233
- Sixth People's Hospital Affiliated with Shanghai Jiao Tong University School of Medicine
-
Sichuan, China, 610041
- West China Hospital, Sichuan University
-
Wuhan, China, 430022
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- The Second Affiliated Hospital of Zhejiang University anesthesiology department
-
Hauptermittler:
- Min Yan, Doctor
-
Kontakt:
- Min Yan, Doctor
- Telefonnummer: +86 15888210247
- E-Mail: zryanmin@zju.edu.cn
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- age 18 more than years;
- undergoing elective bone cancer resection surgery;
- preoperative hemoglobin ≥12 g/dL;
Exclusion Criteria:
- anticipated tourniquet use, endovascular balloon occlusion of the aorta or biopsy only;
- weight < 50Kg or > 100Kg;
- international normalized ratio (INR) >1.5 or platelet count <100 × 10^9/L;
- cardiopulmonary insufficiency;
- hepatic and renal dysfunction;
- active infectious disease;
- allergy to colloid solution;
- pregnancy;
- declined participation in the study or declined blood transfusion
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: Control group
Except for not undergoing ANH, other care managements are the same as the experimental group |
|
|
Experimental: ANH group
Patients in the ANH group had whole blood withdrawn after induction of anesthesia. Meanwhile, patients receive colloid solution according to the volume of blood withdrawn. |
The whole blood is withdrawn after induction of anesthesia. Blood is withdrawn from a large-bore catheter and stored in blood bags. Meanwhile, patients receive colloid solution according to the volume of blood withdrawn. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Perioperative red blood cell transfusion rate
Zeitfenster: hospital discharge, an average of 10 days
|
The number of patients receiving RBCs transfusion from the start of surgery to hospital discharge. |
hospital discharge, an average of 10 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The rate of perioperative transfusion of allogeneic blood products
Zeitfenster: hospital discharge, an average of 10 days
|
This includes blood products such as plasma and platelets, erythrocytes |
hospital discharge, an average of 10 days
|
|
Wound drainage volume
Zeitfenster: hospital discharge, an average of 10 days
|
Accumulated amount of wound drainage after surgery |
hospital discharge, an average of 10 days
|
|
Unplanned re-operation
Zeitfenster: hospital discharge, an average of 10 days
|
Unplanned re-operation due to bleeding, infection or other reasons |
hospital discharge, an average of 10 days
|
|
Perioperative hemoglobin concentration
Zeitfenster: hospital discharge, an average of 10 days
|
hemoglobin concentration during hospitalization |
hospital discharge, an average of 10 days
|
|
The coagulation function tests during the perioperative period
Zeitfenster: hospital discharge, an average of 10 days
|
This includes thromboelastography result |
hospital discharge, an average of 10 days
|
|
Complication
Zeitfenster: hospital discharge, an average of 10 days
|
embolic events, pulmonary complications, infection, acute kidney injury, death. Diagnose according to radiologic examination, sign and symptom |
hospital discharge, an average of 10 days
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- 2026 0947
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .